Biologics Testing Market: By Product Type (Instruments, Kits and Reagents, Services), By Test (Sterility Test, Endotoxin Test, Cell Line Authentication and Characterization, Residual Host Contamination Test, Others), By Application (Cellular and Gene related, Blood and Blood Products, Vaccines, Stem cell Research, Others), By Geography. 

Biologics Testing Market size was valued at US$ 3.2 Bn in 2022, growing at a significant CAGR of 11.8% from 2023-2029. The biologics testing market report provides in-depth analysis of the impact of COVID-19 on the market, along with revised biologics testing market size due to the effects of the coronavirus. The increase in R&D investment in biopharma industry coupled with the increase in the new product launches are expected to bolster the market growth over the forecast period.Biologics are complex compounds made from the genes of live creatures and combined utilising modern DNA technologies. Biologics are cutting-edge medications that are used to treat cancer, cardiovascular disease, rheumatoid arthritis, and other illnesses. Large molecules such as monoclonal antibodies and recombinant proteins are classified as biologics, and their safety ensures patient safety because they are utilised to treat the diseases listed above. Recombinant proteins, tissues, genes, allergens, cells, blood components, and vaccinations are all examples of biologic medications made from live creatures. Biologics are items that are made from living organisms and have specific properties.For new product categories, biological safety assessment is critical. Biological safety testing is done to guarantee that vaccines and biopharmaceuticals are not contaminated and that they meet safety quality standards. Kits and reagents, as well as instruments, make up the product segment.